Press release
Non-Small Cell Lung Cancer Therapeutics Market Size to Reach US$ 64.92 Billion by 2033 as Precision Oncology Advances
Non-Small Cell Lung Cancer Therapeutics Market Size
NSCLC treatment is increasingly shifting toward biomarker-driven approaches that match therapies with specific genetic alterations. Recent regulatory activity involving HER2- and ROS1-targeted medicines, together with the expansion of companion diagnostic testing, is strengthening the role of precision treatment in advanced NSCLC.
Download Free Sample Report: https://www.datamintelligence.com/download-sample/non-small-cell-lung-cancer-therapeutics-market?indhu
Recent Developments in the Non-Small Cell Lung Cancer Therapeutics Market
United States
✓ In September 2026, AstraZeneca and Daiichi Sankyo reported 14.3-month median progression-free survival for Enhertu in first-line HER2-mutant advanced NSCLC in the Phase III DESTINY-Lung04 trial.
✓ In July 2026, Nuvalent received FDA approval for zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive NSCLC after at least one prior ROS1 TKI.
✓ In February 2026, Boehringer Ingelheim's zongertinib (Hernexeos) received FDA accelerated approval for HER2-mutant unresectable or metastatic non-squamous NSCLC.
Japan
✓ In September 2026, Chugai received MHLW approval for FoundationOne CDx as a companion diagnostic for lorlatinib in patients with ALK fusion gene-positive NSCLC.
✓ In September 2026, Takeda announced new TAK-928 clinical data in immunotherapy-resistant and previously untreated NSCLC, with a new non-squamous NSCLC sub-trial added to the Phase III MarsLight-11 study.
✓ In August 2026, AstraZeneca and Daiichi Sankyo reported positive Phase III DESTINY-Lung04 results for Enhertu in first-line HER2-mutant advanced NSCLC, supporting further regulatory discussions.
Mergers and Acquisitions
✓ GSK & Nuvalent - June/July 2026: GSK agreed to acquire and subsequently completed the acquisition of Nuvalent, adding zidesamtinib, neladalkib and NVL-330 to its oncology portfolio for ROS1-, ALK- and HER2-altered NSCLC.
✓ AstraZeneca & Dizal Pharmaceutical - July 2026: AstraZeneca entered an exclusive global licensing agreement for Zegfrovy (sunvozertinib), an oral EGFR inhibitor approved for EGFR exon 20 insertion NSCLC, with a $600 million upfront payment and up to $900 million in milestone payments.
✓ AstraZeneca & Daiichi Sankyo - August 2026: The companies reported positive Phase III results for Enhertu (trastuzumab deruxtecan) in first-line HER2-mutant advanced NSCLC, supporting its potential expansion into an earlier treatment setting.
✓ AstraZeneca & Daiichi Sankyo - September 2026: Updated DESTINY-Lung04 results showed 14.3 months median progression-free survival for first-line Enhertu in HER2-mutant advanced NSCLC, compared with standard chemotherapy plus pembrolizumab.
Non-Small Cell Lung Cancer Therapeutics Market Trends
Expansion of Targeted Therapies
Targeted therapy remains a major area of innovation as drug developers focus on molecular alterations including EGFR, HER2, ROS1 and RET. New approvals and expanded indications are broadening treatment options for biomarker-defined patient populations.
Increasing Role of Companion Diagnostics
The integration of molecular testing with treatment selection is becoming increasingly important. FDA-authorized companion diagnostic tools are being used to identify biomarkers such as EGFR, KRAS and HER2, supporting more individualized treatment decisions.
Get 20% complimentary customization within the report: https://www.datamintelligence.com/customize/non-small-cell-lung-cancer-therapeutics-market?indhu
Market Segmentation
By Type
Adenocarcinoma led with an estimated 52% share, reflecting its position as the most common NSCLC subtype and the broad availability of biomarker-directed treatment options. Squamous cell carcinoma accounted for 29%, followed by large cell carcinoma at 8%, adenosquamous carcinoma at 6%, and sarcomatoid carcinoma at 5%. The distribution reflects differences in disease prevalence and the availability of targeted and systemic treatment approaches across histological subtypes.
By Treatment
Immunotherapy held the largest share at an estimated 31%, supported by the established role of immune checkpoint inhibitors across multiple stages and biomarker-defined NSCLC populations. Targeted therapy accounted for 27%, driven by treatments directed at actionable molecular alterations. Chemotherapy represented 20%, followed by radiation therapy at 12%, photodynamic therapy at 4%, laser therapy at 2%, and other treatments at 4%. The treatment mix reflects increasing personalization of NSCLC management alongside continued use of established modalities.
Regional Analysis
North America
North America generated an estimated 36% of global market revenue, with the United States accounting for the majority of regional demand. Strong oncology infrastructure, widespread molecular testing and access to immunotherapy and targeted therapies support substantial NSCLC treatment utilization.
Europe
Europe accounted for approximately 28% of global revenue, supported by established cancer-care systems, specialist oncology centers and increasing adoption of biomarker-guided treatment. Germany, the United Kingdom, France, Italy and Spain represent important markets.
Asia Pacific
Asia Pacific represented an estimated 23% share, with China, Japan, South Korea, India and Australia contributing significant demand. A large lung-cancer patient population, expanding oncology infrastructure and increasing availability of advanced therapies are supporting market development.
Key Players in the Non-Small Cell Lung Cancer Therapeutics Market
Major companies operating in the market include F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, and Johnson & Johnson Services, Inc. These companies are involved in targeted therapies, immunotherapies, chemotherapy products, clinical development programs and biomarker-driven treatment strategies.
Company Profiles
AstraZeneca
AstraZeneca maintains a broad oncology portfolio covering targeted therapies and other advanced cancer treatments. Its NSCLC activities include medicines and clinical programs focused on molecularly defined patient populations.
Bayer AG
Bayer is expanding its precision-oncology presence through targeted medicines for molecularly defined cancers. Its NSCLC portfolio includes therapies addressing HER2-driven disease.
Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=non-small-cell-lung-cancer-therapeutics-market?indhu
Conclusion
The NSCLC therapeutics market is being reshaped by precision oncology, biomarker testing and the development of therapies targeting specific molecular alterations. Recent regulatory activity in HER2-, ROS1- and RET-driven disease highlights the continued expansion of targeted treatment options.
As pharmaceutical companies advance targeted medicines, immunotherapies and combination approaches, molecular diagnostics and patient-specific treatment selection are expected to remain important components of NSCLC care through 2033.
FAQs
Q: What is the projected size of the global non-small cell lung cancer therapeutics market?
A: The market is projected to reach US$ 64.92 billion by 2033, expanding at a CAGR of 11.7% during 2025-2033.
Q: Which treatment segment is expected to dominate the market?
A: Targeted therapy is expected to dominate, supported by advances in biomarker testing and therapies designed for specific genetic alterations.
Q: What are the major trends shaping NSCLC therapeutics?
A: Key trends include precision oncology, targeted therapies, companion diagnostics, immunotherapy combinations and development of treatments for molecularly defined patient groups.
Q: Who are the key players in the NSCLC therapeutics market?
A: Major players include Roche, Mylan, Teva, Pfizer, Novartis, Bayer, Eli Lilly, Merck, AstraZeneca and Johnson & Johnson.
Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Small Cell Lung Cancer Therapeutics Market Size to Reach US$ 64.92 Billion by 2033 as Precision Oncology Advances here
News-ID: 4642427 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Electric Vehicle Fluids Market Expands Rapidly as 20 Million EV Sales Increase T …
Market Size and Growth 2026
Global electric vehicle sales surpassed 20 million units in 2025, up from 17.3 million in 2024, according to Castrol, expanding the addressable market for specialized transmission fluids, thermal-management fluids, greases, and other EV-specific formulations. The increase in EV volumes is strengthening demand for fluids engineered for high-voltage systems, fast charging, lower energy losses, and battery thermal control. In November 2025, Castrol also partnered with LION Smart…
Smart Coatings Market Advances as AkzoNobel Invests €7.5 Million in Next-Gener …
AkzoNobel inaugurated a €7.5 million innovation laboratory in Sassenheim, Netherlands, in September 2026, strengthening its global R&D capabilities for powder coatings. The facility is focused on developing next-generation, solvent-free and energy-efficient coatings, including lower-temperature curing technologies designed to reduce energy consumption while improving coating performance, product lifetime and material efficiency. The investment adds dedicated research capacity to an area closely aligned with smart-coating demand for multifunctional, durable and sustainability-oriented surface…
Cultured Meat Market Gains Scale with Meatly's £10.4 Million Investment in 20,0 …
Market Size and Growth 2026
The global Cultured Meat market reached an estimated US$ 487.6 million in 2025 and is expected to reach US$ 2.96 billion by 2035, growing with a CAGR of 19.8% during the forecast period 2026-2035.
The cultured meat market is moving toward larger-scale commercial production as Meatly secured £10.4 million in Series A funding in May 2026 to develop a 20,000-liter bioreactor facility in London, described by the…
Superhydrophobic Coatings Market Gains Traction as P2i Secures €8 Million Inve …
P2i secured an initial €8 million investment from Jolt Capital in 2025, with Jolt taking a controlling stake in the company. The funding is supporting the expansion and diversification of P2i's protective nanotechnology platform, which has been deployed on more than one billion devices. The development strengthens commercial opportunities for water-repellent and barrier coatings across electronics, automotive, medical and industrial applications, while increasing demand for scalable, durable surface-treatment technologies.
The…
More Releases for NSCLC
NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care
The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market.
Historically, NSCLC was…
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
